Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs ranibizumab for retinopathy of prematurity
ChiCTR2000037469Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in retinopathy of prematurity (ROP) comparing Aflibercept arm with Ranibizumab arm (2 arms). Primary endpoint: Recurrence rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
afliberceptranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on ChiCTR2000037469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037469.